Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide Once Weekly vs Insulin Glargine in T2DM (DURATION-3)
NCT00641056Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2008
- Primary completion
- May 2009
- Modality
- Peptides
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial of exenatide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by AstraZeneca. Primary endpoint: Change in HbA1c From Baseline to Week 26. Started Apr 2008; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00641056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00641056.